|
- 2016
肌萎缩侧索硬化预后相关的血液学标志物
|
Abstract:
[1] | Ikeda K, Hirayama T, Takazawa T, et al. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study[J]. Intern Med, 2012, 51(12): 1501-1508. |
[2] | Kerentz AJ, Williams AC, Nattrass M. Abnomal regulation of carbohydrate metabolism in motor neurone disease[J]. Diabetes Res, 1991, 16(2): 93-99. |
[3] | Dupuis L, Oudart H, René F, et al. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model[J]. Proc Natl Acad Sci U S A, 2004, 101(30): 11159-11164. |
[4] | Barroso E, Rodriguez-Calvo R, Serrano-Marco L, et al. The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation[J]. Endocrinology, 2011, 152(5): 1848-1859. |
[5] | Jawaid A, Murthy SB, Wilson AM, et al. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS[J]. Amyotroph Lateral Scler, 2010, 11(6): 542-548. |
[6] | Du Y, Chen CP, Tseng CY, et al. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity[J]. Glia, 2007, 55(5): 463-472. |
[7] | Dorst J, Kuhnlein P, Hendrich C, et al. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis[J]. J Neurol, 2011, 258(4): 613-617. |
[8] | Hashizume A, Katsuno M, Banno H, et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy[J]. Brain, 2012, 135(pt 9): 2838-2848. |
[9] | Paganoni S, Deng J, Jaffa M, et al. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis[J]. Muscle Nerve, 2011, 44(1): 20-24. |
[10] | Keizman D, Ish-Shalom M, Berliner S, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress?[J]. J Neurol Sci, 2009, 285(1-2): 95-99. |
[11] | Thau N, Knippenberg S, Korner S, et al. Decreased mRNA expression of PGC-1alpha and PGC-1alpha-regulated factors in the SOD1G93A ALS mouse model and in human sporadic ALS[J]. J Neuropathol Exp Neurol, 2012, 71(12): 1064-1074. |
[12] | Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review[J]. Amyotroph Lateral Scler, 2009, 10(5-6): 310-323. |
[13] | Chiò A, Calvo A, Bovio G, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study[J]. JAMA Neurol, 2014, 71(9): 1134-1142. |
[14] | Zoccolella S, Simone IL, Capozzo R, et al. An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis[J]. J Neurol, 2011, 258(2):238-243. |
[15] | Ruggiero C, Cherubini A, Lauretani F, et al. Uric acid and dementia in community-dwelling older persons[J]. Dement Geriatr Cogn Disord, 2009, 27(4): 382-389. |
[16] | Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis[J]. Amyotroph Lateral Scler Other Motor Neuron Disord, 2000, 1(5): 293-299. |
[17] | Korner S, Hendricks M, Kollewe K, et al. Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis(ALS): impact on quality of life and therapeutic options[J]. BMC Neurol, 2013, 13:84. doi: 10.1186/1471-2377-13-84. |
[18] | Reich-Slotky R, Andrews J, Cheng B, et al. Body mass index(BMI)as predictor of ALSFRS-R score decline in ALS patients[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2013, 14(3): 212-216. |
[19] | Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism[J]. Physiol Rev, 2000, 80(3): 1107-1213. |
[20] | Reynolds A, Laurie C, Lee Mosley R, et al. Oxidative stress and the pathogenesis of neurodegenerative disorders[J]. Intern Rev Neurobiol, 2007, 82: 297-325. |
[21] | Weisskopf MG, OReilly E, Chen H, et al. Plasma urate and risk of Parkinsons disease[J]. Am J Epidemiol, 2007, 166(5): 561-567. |
[22] | Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase[J]. Drug Saf, 2007, 30(6): 515-525. |